Mounting evidence suggests a role for alternative splicing (AS) of transcripts in the normal physiology and pathophysiology of the pancreatic β-cell. In the apparent absence of RNA repair systems, RNA decay pathways are likely to play an important role in controlling the stability, distribution and diversity of transcript isoforms in these cells. Around 35% of alternatively spliced transcripts in human cells contain premature termination codons (PTCs) and are targeted for degradation via nonsense-mediated decay (NMD), a vital quality control process. Inflammatory cytokines, whose levels are increased in both type 1 (T1D) and type 2 (T2D) diabetes, stimulate alternative splicing events and the expression of NMD components, and may or may not be associated with the activation of the NMD pathway. It is, however, now possible to infer that NMD plays a crucial role in regulating transcript processing in normal and stress conditions in pancreatic β-cells. In this review, we describe the possible role of Regulated Unproductive Splicing and Translation (RUST), a molecular mechanism embracing NMD activity in relationship to AS and translation of damaged transcript isoforms in these cells. This process substantially reduces the abundance of non-functional transcript isoforms, and its dysregulation may be involved in pancreatic β-cell failure in diabetes.

Keywords: β-cell, insulin secretion, transcript, nonsense-mediated decay, RNA decay, RNA processing

INTRODUCTION

Diabetes mellitus currently affects ~460 million adults worldwide and its incidence is expected to exceed 700 million by 2045 (1). Both T1D and T2D – the latter being the predominant form – involve defective pancreatic β-cell function, and a contribution of inflammatory processes which is most acute in the former. β-Cell death is marked in T1D: typically >80% of the cell mass is lost, though this figure is lower in some patients, particularly those with later disease onset (2), but more limited in T2D (3) where dysfunction predominates (4). The molecular mechanisms involved in β-cell dysfunction and loss in both settings are only partly understood.
ALTERTATIVE SPLICING (AS); IMPLICATIONS IN β-CELLS

Non-coding interspaced sequences, namely introns, are removed by the spliceosome, a dynamic RNA-protein complex, during transcription from precursor-mRNAs (13, 14). Around 90%–95% of human transcripts are thought to leave the nucleoplasm as pre-mRNAs that need further splicing and processing to become a mature mRNA (15). Alternate (or alternative) isoforms created as pre-mRNAs that need further splicing and processing to become a mature mRNA (15). Alternate (or alternative) isoforms created either by switching the usual promoter to alternative promoter of a mature mRNA (15). Alternate (or alternative) isoforms created either by switching the usual promoter to alternative promoter of a mature mRNA (15).

Alternative splicing, an evolutionarily post-transcriptional pre-mRNA processing process, produces multiple distinct transcript variants of most human genes (16, 17). The mechanisms and biology of splicing and alternative splicing have been extensively reviewed (18–20). As described previously (15) and in Figure 1B, AS can involve inclusion or skipping (exclusion) of an exon, mutually exclusive exons, alternative 5′ donor splice sites, and alternative 3′ acceptor splice sites and intron retention in mRNAs (15). AS is a consequence of interactions between RNA binding proteins (RBPs) and splicing regulatory elements (SREs) in pre-mRNAs. The Serine Arginine rich proteins (SRs) are a family of constitutive or regulatory RNA binding proteins recognize pre-mRNA SREs through interaction with the N-terminal and C-terminal domains enriched with arginine (R) and serine (S) sequences. These then interact with other proteins and/or SREs to enhance splicing by recruiting the spliceosome (21). On the other hand, the second class of RBPs, members of the heterogeneous nuclear ribonucleoprotein (hnRNP) protein family, have been shown to antagonize SR functions by competing for binding to exonic splicing enhancers (ESE) or intronic splicing suppressors (ISS) (21, 22).

Alternative splicing is observed in all human tissues, but has been most extensively studied in neurons (23, 24). Thus, aberrant alternative splicing of the pre-mRNAs encoding calcium signalling transducers affects neuronal function and causes neurodegenerative diseases (25–27). In the past decade, pancreatic β-cell transcriptomic analyses have revealed differential expression profiles of the RBPs and splicing factors which are abundantly expressed in neurons, and whose genetic ablation can lead to impairments in insulin secretion and reduced β-cell viability (28–30).

It is now established that alternative splicing plays an important role in β-cell function and viability. Glucose, a major regulator of pancreatic β-cell function (31), strongly affects insulin gene expression, biosynthesis, and secretion, through multiple mechanisms including changes in transcription, pre-mRNA alternative splicing, translation and mRNA stability (32–34). Insulin intron-2-containing pre-mRNA levels increased six-fold within an hour of a human islet exposure to high glucose, whereas increases in mature mRNA did not occur before 48 h of exposure (35), suggesting that substantial of insulin production is exerted at the level of pre-mRNA alternative splicing. Another study (36) showed that alternative splicing of the insulin receptor is regulated by insulin signalling and modulates β-cell survival in an autocrine pathway involving insulin secretion, binding to and activation of insulin receptors in human and mouse islets and in clonal MIN6 cells.

Several lines of evidence support the importance of regulated AS in inflammatory stresses in pancreatic β-cells, as reviewed previously (28, 37). The pro-inflammatory cytokines interleukin-1β (IL-1β) and interferon-γ (IFNy) upregulate >30 splicing factors, affecting alternative splicing of 35% of genes in the human islet transcriptome (9, 37). Genetic manipulation of several RBP candidates involved in alternative splicing, as listed in Table 1, impaired insulin secretion and sensitised β-cells to basal and/or cytokine-induced toxicity. These changes may reflect
deregulation of transcript isoforms encoding anti/pro-apoptotic proteins as well as those annotated in exocytosis and secretory pathways in pancreatic β-cells (28, 40, 41). Finally, genome-wide RNA sequencing revealed that three transcript isoform variants of CD137 were associated with T1D development in the NOD mice (42).

At present, there is little direct evidence that genetic variants in the genes involved in components of the NMD pathway are involved in altered T2D risk (43). Nevertheless, alternative splicing of genes which are implicated may be relevant. For example, variants in the Transcription factor 7–like 2 (TCF7L2) gene are strongly associated with T2D risk in man (44–47). Mapping of TCF7L2 splice variants revealed a specific pattern in pancreatic islets, with variants carrying exons 4 and 15 correlated with glycated haemoglobin A1c (HbA1c) (48). The presence of deleterious TCF7L2 splice variants (i.e., exons 13-16) was also suggested to be a mechanism of β-cell failure in T2D mouse models (49). Although deletion of TCF7L2 selectively in the

**TABLE 1 | Examples of the function of alternative splicing regulators in β-cells.**

| Transcript targets in β-cells | Knockout/downregulation phenotypes in β-cells | References |
|------------------------------|-----------------------------------------------|------------|
| NOVA1 INSR, PLCγ1, SNAP-25   | • Increase in basal and cytokine-induced cell death • Impairment of GSIS | (38)       |
| NOVA2                        | • Increase in basal and cytokine-induced cell death • no effect on GSIS | (39)       |
| RBFOX1 (A2BP1) Gsn, Cacna1c, | • No effect on apoptosis • Increase in GSIS | (39)       |
| RBFOX2 (RBM9)                | • No effect on apoptosis • Increase in GSIS and insulin content | (39)       |
| ELAVL4                       | • Increase in apoptosis in basal condition, but decrease in cytokine-induced apoptosis • no effect on GSIS | (39)       |
| SRSF6 (SRp55)                | • Increase in apoptosis in basal condition • Impairment of GSIS • Induction of ER stress | (30)       |

**FIGURE 1 | Scheme of alternative transcript isoforms as a result of (A) alternative promoters and post-transcriptional alternative splicing events of pre-mRNAs (B).**
isoforms are (mis-)expressed in pancreatic pancreas (50) or β-cell (51) in mice lowers β-cell function, increased levels of TCF7L2 mRNA are associated with elevated diabetes risk in man (52, 53), with the latter study reporting increased levels of the 3’ exon (and 15 of 18 exons overall) in islets of carriers of the risk rs7903146 allele. However, and as previously discussed (51), risk allele-dependent alternative splicing of the TCF7L2 gene in β-cells may affect the inclusion of a “CRARF” motif in the expressed protein and, as such, may impact the transcriptional activity of this factor (i.e., lowered transcriptional activity despite an increased overall transcript load).

The circadian clock has recently been shown to modulate synchronicity of insulin secretion in dark-light phases by regulating the alternative splicing of pre-mRNAs coding for proteins involved in insulin biosynthesis and exocytosis in primary mouse β-cells. The circadian clock core transcription factors CLOCK and BMAL1 autonomously determine oscillatory regulation of ~27% of the β-cell transcript isoforms corresponding to genes coding for proteins that are involved in the assembly, trafficking, and fusion of secretory vesicles at the plasma membrane (54). Disruption of the CLOCK and BMAL1 genes perturbs rhythmic genome-wide alternative splicing of pre-mRNAs encoding regulators of insulin biosynthesis and secretion in murine insulin-producing cell lines and primary β-cells (41, 54). A later exploration of the underlying mechanisms revealed that thyroid hormone-receptor-associated protein 3 (THRAP3), an RNA-binding protein, modulates circadian clock-dependent alternative splicing of calcium/calmodulin-dependent serine protein kinase (Cask) and MAP kinase-activating death domain (Madd). Consistent with findings of exon skipping due to circadian clock perturbation, CRISPR-Cas9-mediated deletion of exons-11 and -26 of Cask and Madd pre-mRNAs, respectively, impairs insulin secretion in murine insulin-producing β-cells (41). Madd knockout mice developed hyperglycaemia associated with impaired insulin secretion in mice (55).

Alternatively spliced transcript variants can produce functionally different protein isoforms with altered amino acid sequences and protein domains, resulting in modification of activity. This, in turn, may drive alterations in protein localization, interaction with binding partners or post-translational polypeptide processing (56, 57). A substantial number of alternatively spliced variants contain a premature termination codon (PTC) or other mRNA “discrediting” features such as an upstream open reading frame (uORF), long 3’ untranslated region (UTR) or the retention of introns after stop codons (58, 59). Any of these could potentially render the mRNA a target for nonsense-mediated decay (60–62). Whether these isoforms are (mis-)expressed in pancreatic β-cells in diabetes – for example as a result of inflammatory or metabolic stresses – remains to be explored.

**THE NMD PATHWAY: BIOLOGY AND EMERGING ROLE IN β-CELLS**

The nonsense-mediated decay pathway, originally identified as an RNA surveillance mechanism, eliminates aberrant RNAs harbouring PTCs (63). Computational and experimental results indicate that roughly a third of reliably inferred alternative splicing events in humans result in mRNA isoforms that harbour a PTC (64, 65). PTCs can arise in cells through various mechanisms: germline or somatic mutations in DNA; errors in transcription; or post-transcriptional mRNA damage or errors in processing, notably including alternative splicing (66). PTCs have been implicated in approximately 30% of all inherited diseases, indicating that the NMD pathway plays a vital role in survival and health (11, 67). Failure to recognize and eliminate these unproductive transcripts seems likely to result in the production of truncated dysfunctional proteins that directly perturb cell function or lead to an accumulation of misfolded proteins that accumulate in the ER to cause ER stress.

The human NMD machinery is complex and involves multiple proteins including Upf1, Upf2, Upf3a, Upf3b, Smg1, Smg5, Smg6, And Smg7 (See Table 2). Together, these are responsible for the detection and decay of PTC-containing transcripts (Figure 2A). ATPase-dependent RNA helicases play a central role in NMD activity. Thus, the ability of UPF1 to selectively target PTC-containing mRNAs depends on its ATPase and helicase activities (59, 72). Additionally, activation of NMD requires an interaction between Upf1 and protein partners on the targeted mRNA. These partners consist of Upf2 that forms a bridge between Upf1 and Upf3, forming the Upf1–Upf2–Upf3 complex (66, 73). However, in addition to canonical NMD pathway in which all key NMD components function on target transcripts, NMD is also activated (in) dependent of some of its key factors including Upf2 and Upf3 with a cell-type specific manner. Thus, NMD should be seen as a “branched pathway”, with the different branches defined by autoregulatory feedback loops (Figure 2B) (58, 66, 74).

Upf1 promiscuously binds to both NMD-targeted and non-targeted mRNAs undergoing translation (75). On PTC-containing mRNAs, Upf1 and its associated phosphoinositide 3-kinase (PI3K)-like kinase, Smg1 act as a clamp to bind to eukaryotic releasing factors 2 and 3 (eRF2 and eRF3) to form a surveillance complex. The exon-exon junctions at least 50 nucleotides downstream of stop codons possesses a nucleation point where the EJC, Upf2, and Upf3b bind as a foundation of a decay-inducing complex whose Interaction with the surveillance complex triggers Upf1 phosphorylation, dissociation of eRF1 and eRF3, and conformational remodelling of NMD. This adopts Upf1 activity to resolve mRNA secondary structure by its helicase activity, allowing access to the mRNA of the NMD effector proteins Smg5-7 (59, 72–77). The decay of targeted transcripts then takes place through the following steps: recruitment of the endoribonuclease Smg6, which catalyses PTC-proximal mRNA cleavage, producing 5’ and 3’ cleavage fragments that are degraded by exoribonucleases (73, 78, 79); recruitment of the Smg5–Smg7 heterodimer, which bridges an interaction with the carbon catabolite repressor protein 4 (CCR4)-NOT deadenylase complex, thereby shortening the poly(A) tail to stimulate mRNA decapping by the general decapping complex (80–82); recruitment of the decapping enhancer Proline-rich nuclear receptor co-activator 2 (PNRC2), possibly in a complex with SMG5, which
recruits the general decapping complex (83); and/or direct recruitment of the general decapping complex (73, 79, 84). Decapped mRNA is in turn degraded from the 5'−3' end by the Xrn1 exoribonuclease and from the 3' terminus by the Dis3L1 and/or Dis3L2 exosome complex (85, 86). Xrn1 has also been shown to promote general 5'−3' co-translational mRNA decay following the last translating ribosome (85). These degradation pathways are not mutually exclusive, and their balance varies depending on the particular mRNA or organism (73, 86).

NMD pathways have been studied in different human and mouse tissues, and most recently by one of us (SMG) in human and rodent islets (7). These studies revealed that NMD components are differentially up/down-regulated by inflammatory cytokines and glucolipotoxicity. Genetic suppression of the key NMD component Smg6, an endoribonuclease which cleaves NMD targeted transcripts at the proximate location of the PTC (Table 2), alleviated cytokine-mediated toxicity associated with increased insulin biosynthesis and glucose−induced insulin secretion in INS-1 cells, a rat insulinoma-derived insulin-producing cell line. This study also revealed that nitrooxidative stress is mechanistically involved in cytokine-mediated up-regulation of NMD components, since chemical inhibition of inducible nitric oxide (iNOS) by N-methyl-L-arginine (NMA), limited mRNA levels of its components. At the protein level, control is also exerted by protein stabilization of proteins involved in regulation such as Upf3a, an RNA-binding protein suppressing protein Staufen 1 competes with Upf1 of the NMD, and auto-regulatory feedback (Figure 2B) (87–90). The feedback loop has been reported to be exerted at both the mRNA and protein levels of the NMD factors. At the mRNA level, NMD controls the rate-limiting mRNA levels of its components. At the protein level, control is also exerted by protein stabilization of proteins involved in regulation such as Upf3a, an RNA-binding protein suppressing NMD activity (91, 92). It is therefore is not surprising that different branches of the NMD pathway have different efficiency profiles in different tissues (58, 93). Nevertheless, it will be important to determine what branches of NMD control pathway activity in stress conditions in primary pancreatic β-cells.

Could NMD transcript variations such as genetic mutations, SNPs and environmental factors affecting NMD activity be associated with cause and development of diabetes? Considering the emerging role of NMD in regulating transcript processing in pancreatic β-cells, we sought to understand whether transcript variants of NMD components are associated with T2D. Our interrogation of publicly-available GWAS data (type2diabetesgenes.org) reveals that an accumulated list of the NMD transcript variants with surprisingly high burden of natural loss-of-function variation including stop-gained, essential splice, and frameshift variants are significantly associated with T2D (p<0.05) (Figure 3A). In addition, chromatin analysis using ATAC-sequencing, a popular method for determining chromatin accessibility across the genome, indicates high chromatin accessibility to enhancers and subsequent strong transcription upon the key NMD components, e.g., Upf1 and Upf2 and Upf3a (Figure 3B).

**TABLE 2 | Characteristics of core machinery and effective NMD components.**

| NMD component | MW (kDa) | Alternative names | Localization | Direct NMD interactors | Functions in NMD |
|---------------|---------|------------------|-------------|-----------------------|------------------|
| UPF1 (an ATP-dependent RNA helicase) | 123 | NORF1, RENT1, smg-2 | shuttling to nucleus, but mainly in cytoplasm | UPF2, SMG1, SMG6, SMG7 | ATP-dependent helicase, RNA binding protein; regulated by phosphorylation; direct binding to eRFs, Pnrc2, and decapping factors |
| UPF2 | 148 | RENT2, smg-3 | Perinuclear (cytoplasmic) | UPF1, SMG1, UPF3 | Regulates UPF1 helicase activity; stimulates SMG1 kinase activity; establishes a physical link between UPF1 and UPF3 |
| UPF3A | 55 | RENT3A, UPF3 | shuttling to nucleus, but mainly in cytoplasm | UPF2, EJC | Establishes a physical link between UPF1-UPF2 and the EJC; EJC-independent function unknown |
| UPF3B | 56 | RENT3B, UPF3X | shuttling to nucleus, but mainly in cytoplasm | UPF2, EJC | Establishes a physical link between UPF1-UPF2 and the EJC; EJC-independent function unknown, promotes UPF1 phosphorylation; UPF3B-independent is the NMD branch |
| SMG1 (A P3-kinase-like kinase) | 410 | ATX, LIP | Cytoplasm and nucleus | UPF1, UPF2, SMG8, SMG9 | Phosphorylates UPF1 |
| SMG5 | 114 | EST1B | Cytoplasm and nucleus | UPF1, SMG7 | Forms a complex with SMG7; recruits PP2A for UPF1 dephosphorylation; provides additional binding affinity to phosphorylated UPF1 |
| SMG6 (A endoribonuclease) | 160 | EST1A | Cytoplasm and nucleus | UPF1, EJC | Promotes UPF1 dephosphorylation; directly degrade transcripts at vicinity of the PTC |
| SMG7 | 122 | EST1C | Cytoplasm | UPF1, SMG5 | Forms a complex with SMG5; required for SMG5/7 binding to phosphorylated UPF1; recruits POP2 for mRNA deadenylation |
| SMG8 | 110 | FLJ10587, FLJ23205 | Not identified | SMG1, SMG9 | Regulation of SMG1 kinase activity; induces inactivating conformational changes in SMG1 |
| SMG9 | 58 | FLJ12886 | Not identified | SMG1, SMG8 | Regulation of SMG1 kinase activity; required for SMG1 complex |

This table is extracted from these review articles (58, 68–70).
FIGURE 2 | Simplified canonical model of NMD pathway activation (A) in human cells which is controlled by three different ways so far and yet to be identified (B). Inter-individual variation of NMD efficiency due to transcript variants modifies the presentation of clinical phenotypes and response to the PTC read-through drug PTC124 treatment (B). At early ER stress, UPR suppresses NMD to provide maximum capacity of UPR proteins replenishment. Once ER stress is being resolved, the UPR is downregulated, while NMD is supposed to return to its normal activity to eliminate unproductive transcript isoforms, thereby leading to further downregulation of the UPR as UPR transcripts isoforms are NMD specific targets. Unresolved ER stress induces apoptosis which in turn suppresses NMD pathway to execute the cell to avoid deleterious outcomes (C) (59, 68, 69, 71).
TRANSCRIPT PROCESSING IN THE β-CELL TRANSCRIPTOME

The integrity and accuracy of transcript processing is likely to be crucially important to shape the transcriptome of the β-cell and, in turn, to meet the physiological demands and pathophysiological challenges it faces.

In addition to degrading PTC-containing transcripts (i.e., “unproductive” transcripts) (63), NMD is also involved in normal physiology and in the transcriptional regulation of normal transcripts (i.e., “productive” transcripts), functioning as a fine-tuning mechanism of gene expression (59, 71). In fact, early embryonic lethality of mice depleted of the NMD factors Upf1, Upf2, Upf3a, Smg1, and Smg6 suggests that NMD is important for normal development and growth of the cell (60, 94–97). Whether impaired transcript processing due to deregulated NMD pathway may induce the dedifferentiation of β-cells, as may occur in T2D (98) and possibly T1D (99), or hinders interactions between β- with other cell types in the islet (100, 101) are important questions.

In T2D, a compensatory increase in insulin secretion in response to insulin resistance can stimulate a sequence of “stressful” events in the β-cell (the most important being; ER stress, inflammasome activation with subsequent β-cell-driven cytokine (e.g., IL-1β) production and NF-κB activation and nitroxidative/oxidative stress). Together, these may then

![Figure 3](image-url)

**FIGURE 3** | Number of transcript variants of the NMD pathway components and alternative splicing regulators associated with type 2 diabetes (A) and an ATAC-seq sequencing analysis for chromatin accessibility of the Upf1 gene (B), extracted from publicly available type 2 diabetes datasets.
initiate low-grade inflammation in the islet microenvironment (102, 103). In T1D, a cascade of inflammatory cytokines secreted from the immune cells leads to autoimmune destruction of β-cells (104). Cellular senescence may also be involved (105, 106). The overt loss of functional β-cell mass in T1D is thought, ultimately, to result from accelerated apoptosis (3). ER stress is a common upstream culprit in both T1D and T2D (102, 104). The unfolded protein response, which may lead to ER stress, on the one hand, and NMD on the other, mutually regulate each other in mouse and human tissues and cell lines (71). Thus, UPR transcripts may be NMD-specific targets (58).

The NMD plays a central role in the RUST mechanism to eliminate the PTC-containing transcript isoforms generated due to perturbed AS (107). The degree and magnitude of NMD activity varies among studied mice and human cells and tissues, as reviewed previously (89). In transgenic mice ubiquitously expressing the Men1 gene, the ratio of PTC-containing versus wild-type transcripts was significantly different between adult mouse tissues. Among the tested tissues, testis, ovary, brain, and heart exhibited high NMD activity, measured by strong downregulation, and lung, intestine, and thymus exhibited weak downregulation of the mutant Men1 transcripts compared to wild-type transcripts (108). Unfortunately, neither this study nor others reported NMD efficacy in the pancreas.

Other studies have suggested that NMD efficiency varies among individuals with nonsense mutations e.g., in the cystic fibrosis gene CFTR in response to the drug PTC124, forcing read-through of mutated mRNAs (Figure 2B) (109). The RUST mechanism was first proposed by Lewis and colleagues in 2003 (64). These authors found that 35% (i.e., 1,989 out of 5,693) of alternatively spliced transcript isoforms in the human cell transcriptome were NMD targets since they contained PTCs (64). Several subsequent studies identified a role for incomplete RUST in regulating transcript processing in breast and myelodysplastic syndrome (MDS) cancers, and in neurological disorders such as Alzheimer’s disease and multiple sclerosis (16). However, the role of RUST is completely unknown in transcript processing in pancreatic β-cells. Knowing that pro-inflammatory cytokines regulate alternative splicing events and the NMD pathway in human and rodent primary β-cells (9, 28, 37, 40, 41), we propose a model (Figure 4) in which incomplete RUST leads to accumulation of unproductive transcripts whose translation into unfolded, truncated polypeptides overwhelms ER capacity and consequently drives unresolved ER stress. Consistent with this view, enforcing ribosomal read-through of such PTC-containing mRNAs with the drug PTC124 aggravates cytokine-induced apoptosis and is associated with an increase in ER stress in human islets and INS-1 cells (7).

**PERSPECTIVE: A NEW TYPE OF UNPRODUCTIVE TRANSCRIPT?**

The recent discovery of a special class of bifunctional RNAs, namely coding-noncoding RNAs (cncRNA), implicates another culprit in the pathogenesis of diseases such as Alzheimer’s disease. Amongst the cncRNAs, certain noncoding mRNA isoforms (ncimRNA) of (usually) protein-coding genes quantitatively predominate (110, 111). The precise function and underlying molecular mechanism(s) of action of cncRNAs has been investigated in a few cases (110). Insulin receptor substrate 1 (IRS1), a major substrate and cytoplasmic docking protein for the insulin receptor and insulin-like growth factor receptor, is involved in insulin signalling. The level of IRS1 is highly increased in proliferative cells such as human and mouse cancer cells (110), whereas profoundly decreased in differentiated cells. In addition, whole body Irs1 knockout mice exhibited severe insulin resistance in skeletal muscle and liver, with compensatory β-cell hyperplasia (112). Surprisingly, a further study (113) found that the 5′ UTR of Irs1 mRNA acts as an antisense mRNA to the cell cycle regulator retinoblastoma (Rb).

Intronic or exonic Circular RNAs (circRNAs) are a type of single-stranded noncoding RNAs whose 5′ and 3′ termini are covalently linked by back-splicing of exons from a single pre-mRNA and they are, therefore, stable and resistant to exonuclease degradation (114). With a feature of cell-specificity and being conserved between species, circRNAs play important roles in the development of diseases by modulating post-transcriptional regulation of gene expression (114, 115). Recently, two intronic circRNA borne from murine insulin genes, ci-Ins2 and ci-INS have been reported to control insulin secretion. Thus, silencing of ci-Ins2 in pancreatic islets decreases in the expression of key components of the secretory machinery of β-cells, resulting in impaired pulsatile insulin secretion and calcium signalling (116). Interestingly, these circRNAs were shown to interact with the RNA-binding protein TAR DNA-binding protein 43 KDa (TDIP43) (116), indicating a possible correlation with alternative splicing and pre-mRNA turnover, and eventually NMD activity.

**FIGURE 4** | Deregulation of NMD due to islet inflammation largely influence RUST mechanism of transcript processing and subsequent accumulation of unproductive transcript isoforms, which implicates in β-cell dysfunction, vulnerability, and death.
DISCUSSION

Pancreatic β-cells must fine tune protein synthesis given large fluctuations between low and very high demands for insulin secretion. Post-transcriptional regulation plays an important role (33, 117). Transcript processing is, however, not limited only to alternative splicing events. Other homeostatic pathways including NMD directly, and UPR indirectly, are involved in this fine-tuning. Inflammatory cytokines and glucolipotoxicity are major drivers of ER stress in pancreatic β-cells leading to UPR and NMD activation and are likely needed to efficiently and accurately eliminate unproductive transcript isoforms (Figure 2C). If these remained intact, the production of truncated proteins may exert deleterious effects on β-cell function and viability.

With respect to the identified role of RBPs and alternative splicing factors in pancreatic β-cell function and viability, and given that over 90% of human genes transcribed into at least four transcript isoforms (17, 118–120), we suggest that transcript processing by the RUST mechanism may be mandatory to guarantee functional accuracy and integrity of pancreatic β-cells. In regard to the development, differentiation, function and resilience of pancreatic β-cells in health and in diabetes, we suggest that the following questions represent important areas for future research:

1. What is the role of the NMD in regulating normal transcripts?
2. Can we identify NMD-specific targets?
3. What is the contribution of the NMD to the RUST mechanism of eliminating unproductive transcript isoforms?
4. Do inflammatory and glucolipotoxic stresses exert adverse effects on insulin biosynthesis and secretion, as well as cell viability, through changes in NMD activity?
5. If so, which branches of NMD are involved and are the key components indispensable in normal, stress and disease conditions?

AUTHOR CONTRIBUTIONS

The first draft was written by SG and edited by GR and SG. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported within the independent postdoctoral grant (international mobility, grant number: 9034-00001B) for SMG by the Independent Research Fund Denmark (DIFF-Medical Council). GR was supported by a Wellcome Trust Senior Investigator (WT098424/AIA) and Investigator (WT212625/Z/18/Z) Awards, MRC Programme grants (MR/R022259/1, MR/J0003042/1, MR/L020149/1, MR/R022259/1) and Experimental Challenge Grant (DIVA, MR/L02036X/1), MRC (MR/N00275X/1), Diabetes UK (BDA/11/004210, BDA/15/005275, BDA 16/005485), and Imperial Confidence in Concept (ICiC) grants. This project has received funding from the European Union’s Horizon 2020 research and innovation programme via the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881 (RHAPSODY) to GR.

REFERENCES

1. The International Diabetes Federation (IDF). Available at: https://idf.org/ (Accessed October 26, 2020).
2. Morgan NG, Richardson SJ. Fifty years of pancreatic islet pathology in human type 1 diabetes: insights gained and progress made. Diabetologia (2018) 61:2499–506. doi: 10.1007/s00125-018-4731-y
3. Rahier J, Guoit Y, Goebelbs RM, Sempoux C, Henquin JC. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab (2008) 10 Suppl 1:32–42. doi: 10.1111/j.1463-1326.2008.00969.x
4. Rutter GA, Georgiadou E, Martinez-Sanchez A, Pullen TJ. Metabolic and functional specialisations of the pancreatic beta cell: gene disallowance, mitochondrial metabolism and intercellular connectivity. Diabetologia (2020) 63:1990–8. doi: 10.1007/s00125-020-05205-5
5. Lytrevi M, Castell AL, Postout V, Cnop M. Recent Insights Into Mechanisms of beta-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes. J Mol Biol (2020) 432:1514–34. doi: 10.1016/j.jmb.2019.09.016
6. Eizirik DL, Pasquali L, Cnop M. Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol (2020) 16:349–62. doi: 10.1038/s41574-020-0355-7
7. Ghiasi SM, Krogh N, Tyberg B, Mandrup-Poulsen T. The No-Go and Nonsense-Mediated RNA Decay Pathways Are Regulated by Inflammatory Cytokines in Insulin-Producing Cells and Human Islets and Determine beta-Cell Insulin Biosynthesis and Survival. Diabetes (2018) 67:2019–37. doi: 10.2337/db18-0073
8. Le K, Mitsouras K, Roy M, Wang Q, Xu Q, Nelson SF, et al. Detecting tissue-specific regulation of alternative splicing as a qualitative change in microarray data. Nucleic Acids Res (2004) 32:e180. doi: 10.1093/nar/gnh173
9. Eizirik DL, Sammeth M, Bouckenooghe T, Bottu G, Sisino G, Igoillo-Esteve M, et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet (2012) 8:e1002552. doi: 10.1371/journal.pgen.1002552
10. Jamar NH, Kritsliikgkou P, Grant CM. The non-stop decay mRNA surveillance pathway is required for oxidative stress tolerance. Nucleic Acids Res (2017) 45:6881–93. doi: 10.1093/nar/gkx306
11. Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F. and Dietz HC. Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mates genomic noise. Nat Genet (2004) 36:1073–8. doi: 10.1038/ng1429
12. Park E, Maquat LE. Staufen-mediated mRNA decay. Wiley Interdiscip Rev RNA (2013) 4:423–35. doi: 10.1002/wrna.1168
13. Chen W, Moore MJ. The splicingosome: disorder and dynamics defined. Curr Opin Struct Biol (2014) 24:141–9. doi: 10.1016/j.sbi.2014.01.009
14. Will CL, Luhrmann R. Spliceosome structure and function. Cold Spring Harb Perspect Biol (2011) 3(7):a003707. doi: 10.1101/cshperspect.a003707
15. Ramansukayya TV, Krishnamurthy PR, Grinev VV. The determinants of alternative RNA splicing in human cells. Mol Genet Genomics (2017) 292:1175–95. doi: 10.1007/s00438-017-1350-0
16. da Costa PJ, Menezes J, Romao L. The role of alternative splicing coupled to nonsense-mediated mRNA decay in human disease. Int J Biochem Cell Biol (2017) 91:168–75. doi: 10.1016/j.biocell.2017.07.013
17. Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science (2003) 302:2414–41. doi: 10.1126/science.1090100
18. Briese M, Haberman N, Sibley CR, Faraway R, Elser AS, Chakrabarti AM, et al. A systems view of splicosomal assembly and branchpoints with iCLIP. Nat Struct Mol Biol (2019) 26:930–40. doi: 10.1038/s41594-019-0300-4
Ghiasi and Rutter Unregulated Transcript Processing in Pancreatic β-Cells

35. Evans-Molina C, Garmey JC, Ketchum R, Brayman KL, Deng S, Mirmira RG.
21. Jeong S. SR Proteins: Binders, Regulators, and Connectors of RNA.
20. Jamison SF, Crow A, Garcia-Blanco MA. The spliceosome assembly pathway
29. Dlamini Z, Mokoena F, Hull R. Abnormalities in alternative splicing in
human islets.
28. Han X, Chen J, Xie X, et al. Alternative splicing regulates site-directed DNA
repair in human keratinocytes.
27. Billeter JL, MacLaren R, Large K, et al. Alternative splicing regulates docosahexaenoic
acid metabolism.
26. Barak R, Apkarian V, Beeman FR, et al. Alternative splicing mediates the
synaptic function of a GABAergic inhibitory trans-synaptic network.
25. Rhee LG, Kwon SW, Butt JS, et al. Alternative splicing is required for AMPK
activation in skeletal muscle.
24. Yoon IS, Song CS, Lim YS, et al. Alternative splicing of the alpha-1-adrenergic
receptor regulates basal and nicotine-stimulated renal sympathetic
nerve activity.
23. Prasad NR, Brinkman GR, Estes MA. Alternative splicing of the polycystic
kidney disease 1 transcript.
22. Kachapati K, Bednar KJ, Adams DE, Wu Y, Mittler RS, Jordan MR, et al. Recombinant
soluble CD137 prevents type 1 diabetes in nonobese diabetic mice. J Autoimmun
(2013) 47:94–103. doi: 10.1016/j.jaut.2013.09.002
21. Type 2 diabetes knowledge portal. Available at: http://t2d.huegamp.org/
(Accessed October 26, 2020).
20. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7–like 2 (TCF7L2) gene
confers risk of type 2 diabetes. Nat Genet (2006) 38:320–3. doi: 10.1038/ng1732
19. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-
wide association study identifies novel risk loci for type 2 diabetes. Nature
(2007) 451:858–1. doi: 10.1038/nature06566
18. Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, et al. A common variant in the FTO gene is associated with body mass
index and predisposes to childhood and adult obesity. Science (2007) 316:889–94.
doi: 10.1126/science.1141634
17. Groves CJ, Zeggini E, Minton J, Frayling TM, Weedon MN, Rayner NW, et al. Association analysis of 6,736 U.K. subjects provides replication and
confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial
effect on individual risk. Diabetes (2006) 55:2640–4. doi: 10.2377/jb06-0355
16. Oshima P, Hanson O, Jonsson A, Ronn T, Groop L, Renstrom E. Unique
splicing pattern of the TCF7L2 gene in human pancreatic islets. Diabetologia
(2009) 52:850–4. doi: 10.1007/s00125-009-1293-z
15. Le Bacquer O, Shu L, Marchand M, Neve B, Paroni F, Conte J, et al. TCF7L2
splice variants have distinct effects on beta-cell turnover and function. Hamol
Genet (2011) 20:1906–15. doi: 10.1093/hmg/ddr072
14. da Silva Xavier G, Mondragon A, Sun G, Chen L, McGinty JA, French PM, et al. Abnormal glucose tolerance and insulin secretion in pancreas-specific
TCF7L2-null mice. Diabetologia (2012) 55:2667–76. doi: 10.1007/s00125-012-
2600-7
13. Mitchell RK, Mondragon A, Chen L, McGinty JA, French PM, Fijen J, et al. Selective disruption of Tcf7l2 in the pancreatic beta cell impairs secretory
function and lowers beta cell mass. Hamol Genet (2015) 24:1390–9.
doi: 10.1093/hmg/ddu553
12. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomile T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes.
N Engl J Med (2008) 359:2220–32. doi: 10.1056/NEJMoa0801869
11. Vinuela A, Varshney A, van de Bunt M, Prasad RB, Asplund O, Bennett A, et al. Association analysis of 6,736 U.K. subjects provides replication and
confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial
effect on individual risk. Diabetes (2006) 55:2640–4. doi: 10.2377/jb06-0355
10. Oshima P, Hanson O, Jonsson A, Ronn T, Groop L, Renstrom E. Unique
splicing pattern of the TCF7L2 gene in human pancreatic islets. Diabetologia
(2009) 52:850–4. doi: 10.1007/s00125-009-1293-z
9. Le Bacquer O, Shu L, Marchand M, Neve B, Paroni F, Conte J, et al. TCF7L2
splice variants have distinct effects on beta-cell turnover and function. Hamol
Genet (2011) 20:1906–15. doi: 10.1093/hmg/ddr072
8. da Silva Xavier G, Mondragon A, Sun G, Chen L, McGinty JA, French PM, et al. Abnormal glucose tolerance and insulin secretion in pancreas-specific
TCF7L2-null mice. Diabetologia (2012) 55:2667–76. doi: 10.1007/s00125-012-
2600-7
7. Mitchell RK, Mondragon A, Chen L, McGinty JA, French PM, Fijen J, et al. Selective disruption of Tcf7l2 in the pancreatic beta cell impairs secretory
function and lowers beta cell mass. Hamol Genet (2015) 24:1390–9.
doi: 10.1093/hmg/ddu553
6. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomile T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes.
N Engl J Med (2008) 359:2220–32. doi: 10.1056/NEJMoa0801869
5. Vinuela A, Varshney A, van de Bunt M, Prasad RB, Asplund O, Bennett A, et al. Association analysis of 6,736 U.K. subjects provides replication and
confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial
effect on individual risk. Diabetes (2006) 55:2640–4. doi: 10.2377/jb06-0355
4. Oshima P, Hanson O, Jonsson A, Ronn T, Groop L, Renstrom E. Unique
splicing pattern of the TCF7L2 gene in human pancreatic islets. Diabetologia
(2009) 52:850–4. doi: 10.1007/s00125-009-1293-z
3. Le Bacquer O, Shu L, Marchand M, Neve B, Paroni F, Conte J, et al. TCF7L2
splice variants have distinct effects on beta-cell turnover and function. Hamol
Genet (2011) 20:1906–15. doi: 10.1093/hmg/ddr072
2. da Silva Xavier G, Mondragon A, Sun G, Chen L, McGinty JA, French PM, et al. Abnormal glucose tolerance and insulin secretion in pancreas-specific
TCF7L2-null mice. Diabetologia (2012) 55:2667–76. doi: 10.1007/s00125-012-
2600-7
1. Mitchell RK, Mondragon A, Chen L, McGinty JA, French PM, Fijen J, et al. Selective disruption of Tcf7l2 in the pancreatic beta cell impairs secretory
function and lowers beta cell mass. Hamol Genet (2015) 24:1390–9.
doi: 10.1093/hmg/ddu553
0. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomile T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes.
N Engl J Med (2008) 359:2220–32. doi: 10.1056/NEJMoa0801869
Azzalin CM, Reichenbach P, Khoriauli L, Giulotto E, Lingner J. Telomeric... 1779:538–49. doi: 10.1016/j.bbagen.2008.06.012

Losson R, Lacroute F. Interference of nonsense mutations with eukaryotic messenger RNA stability. Proc Natl Acad Sci USA (1979) 76:5134–7. doi: 10.1073/pnas.76.10.5134

Lewis BP, Green RE, Brenner SE. Evidence for the widespread coupling of... 16:74–23. doi: 10.1016/j.cell.2012.07.029

Filichkin SA, Priest HD, Girvan SA, Shen R, Bryant DW, Fox SE, et al. Repeat containing RNA and RNA surveillance factors at mammalian transcriptional start sites. EMBO J (2014) 34:1630–47. doi: 10.1002/embj.201449947

Goetz AE, Wilkinson M. Stress and the nonsense-mediated RNA decay pathway. Cell Mol Life Sci (2017) 74:3509–31. doi: 10.1007/s00018-017-2537-6

Lewis BP, Hillman RT, Blanchette M, Lareau LF, Garnett AT, et al. Widespread predicted nonsense-mediated mRNA decay of alternatively-spliced transcripts of human normal and disease genes. Bioinformatics (2003) 19 Suppl 1:118–21. doi: 10.1093/bioinformatics/btg1015

Chang YF, Imam JS, Wilkinson MF. The nonsense-mediated decay RNA surveillance pathway. Annu Rev Biochem (2016) 76:51–74. doi: 10.1146/annurev.biochem.76.051010.093009

Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE. Nonsense-mediated decay approaches the clinic. Nat Genet (2004) 36:801–8. doi: 10.1038/ng1403

Losson R, Lacroute F. Interference of nonsense mutations with eukaryotic messenger RNA stability. Proc Natl Acad Sci U S A (2003) 100:189–92. doi: 10.1073/pnas.0136770100

Filichkin SA, Priest HD, Girvan SA, Shen R, Bryant DW, Fox SE, et al. Repeat containing RNA and RNA surveillance factors at mammalian transcriptional start sites. EMBO J (2014) 34:1630–47. doi: 10.1002/embj.201449947

Filichkin SA, Priest HD, Girvan SA, Shen R, Bryant DW, Fox SE, et al. Repeat containing RNA and RNA surveillance factors at mammalian transcriptional start sites. EMBO J (2014) 34:1630–47. doi: 10.1002/embj.201449947
102. Ghiasi SM, Hansen JB, Christensen DP, Tyberg B, Mandrup-Poulsen T. The Connexin 43 Regulator Rotigaptide Reduces Cytokine-Induced Cell Death in Human Islets. *Int J Mol Sci* (2020) 21(12):4311. doi: 10.3390/ijms21124311

103. Ghiasi SM, Dahllof MS, Osmai Y, Osmai M, Jakobsen KK, Aivazidis A, et al. Regulation of the beta-cell inflammasome and contribution to stress-induced cellular dysfunction and apoptosis. *Mol Cell Endocrinol* (2018) 478:106–14. doi: 10.1016/j.mce.2018.08.001

104. Eizirik DL, Mandrup-Poulsen T. A choice of death

105. Thompson PJ, Shah A, Ntranos V, Van Gool F, Atkinson M, Bhushan A.

106. Sampath K, Ephrussi A. CncRNAs: RNAs with both coding and non-coding roles in development.

107. McGlincy NJ, Smith CW. Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense?

108. Zetoune AB, Fontaniere S, Magnin D, Anzukow O, Bhushan A. Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes. *Cell Metab* (2019) 29:1045–1060 e10. doi: 10.1016/j.cmet.2019.01.021

109. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. *Lancet* (2008) 372:719–27. doi: 10.1016/S0140-6736(08)61168-X

110. McGlincy NJ, Smith CW. Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense?

111. Ghiasi SM, Hansen JB, Christensen DP, Tyberg B, Mandrup-Poulsen T. The Connexin 43 Regulator Rotigaptide Reduces Cytokine-Induced Cell Death in Human Islets. *Int J Mol Sci* (2020) 21(12):4311. doi: 10.3390/ijms21124311

103. Ghiasi SM, Dahllof MS, Osmai Y, Osmai M, Jakobsen KK, Aivazidis A, et al. Regulation of the beta-cell inflammasome and contribution to stress-induced cellular dysfunction and apoptosis. *Mol Cell Endocrinol* (2018) 478:106–14. doi: 10.1016/j.mce.2018.08.001

104. Eizirik DL, Mandrup-Poulsen T. A choice of death

105. Thompson PJ, Shah A, Ntranos V, Van Gool F, Atkinson M, Bhushan A.

106. Sampath K, Ephrussi A. CncRNAs: RNAs with both coding and non-coding roles in development.

107. McGlincy NJ, Smith CW. Alternative splicing resulting in nonsense-mediated mRNA decay: what is the meaning of nonsense?

108. Zetoune AB, Fontaniere S, Magnin D, Anzukow O, Bhushan A. Targeted Elimination of Senescent Beta Cells Prevents Type 1 Diabetes. *Cell Metab* (2019) 29:1045–1060 e10. doi: 10.1016/j.cmet.2019.01.021

109. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. *Lancet* (2008) 372:719–27. doi: 10.1016/S0140-6736(08)61168-X

Conflict of Interest: GR has received grant funding and consultancy fees from Sun Pharmaceuticals and Les Laboratoires Servier for unrelated studies.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.